Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Pharmaceuticals to Present at the 12th Annual BIO Investor Forum
SAN DIEGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present a company overview at the 12 th Annual BIO
View HTML
Toggle Summary Conatus Pharmaceuticals to Join Russell Indices on September 30, 2013
SAN DIEGO, Sept. 24, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will be included in the Russell 2000®, Russell 3000® and Russell
View HTML
Toggle Summary Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure (ACLF) Patients
SAN DIEGO, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced initiation of active patient recruitment in a Phase 2b clinical trial of emricasan
View HTML
Toggle Summary Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population
SAN DIEGO, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced initiation of dosing in the Phase 2 clinical trial of emricasan in patients with
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Second Quarter 2013 Financial Results
SAN DIEGO, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter ended June 30, 2013.
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at Stifel Healthcare Conference 2013
SAN DIEGO, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present a company overview at the Stifel Healthcare
View HTML
Toggle Summary Conatus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
SAN DIEGO, July 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the pricing of its initial public offering of 6,000,000 shares of its common
View HTML
Toggle Summary Conatus Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering
SAN DIEGO, June 14, 2013 —Conatus Pharmaceuticals Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock.
View HTML